Gradia Health vs Amgen

Side-by-side comparison of AI visibility scores, market position, and capabilities

Amgen leads in AI visibility (88 vs 37)
Gradia Health logo

Gradia Health

EmergingHealthcare

General

Metabolic health program combining continuous glucose monitoring with nutrition coaching; prediabetes prevention for employer wellness programs competing with Virta Health and Omada.

AI VisibilityBeta
Overall Score
D37
Category Rank
#489 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
38
Perplexity
40
Gemini
37

About

Gradia Health is a digital health company providing personalized metabolic health programs that combine continuous glucose monitoring (CGM), one-on-one nutrition coaching, and lifestyle interventions to prevent and reverse chronic metabolic conditions including prediabetes, insulin resistance, and metabolic syndrome. Founded in 2020 in San Francisco, Gradia raised $4.33-6.83 million in funding and generated $1.1 million in revenue in 2024, serving patients through both employer-sponsored health benefits and direct-to-consumer program enrollment.\n\nGradia's program pairs participants with a continuous glucose monitor that provides real-time blood sugar data, then connects them with registered dietitians and health coaches who use that data to personalize meal plans and behavioral interventions. The CGM data reveals how individual participants' blood sugar responds to specific foods, exercise, sleep, and stress — enabling precision nutrition recommendations that go beyond generic dietary guidelines. Programs typically run 3-6 months and focus on sustainable lifestyle changes supported by regular coach check-ins.\n\nIn 2025, Gradia operates in the rapidly growing metabolic health digital platform market alongside Levels Health (CGM for optimization), Virta Health (type 2 diabetes reversal), Noom (behavioral weight loss), and Omada Health (preventive health coaching) for the employer wellness and direct-to-consumer metabolic health programs. The employer-sponsored wellness market is particularly active as self-insured employers recognize that preventing metabolic disease is significantly cheaper than treating its downstream consequences (heart disease, type 2 diabetes, kidney disease). Gradia's 2025 strategy focuses on growing employer contracts with self-insured mid-market companies, deepening the CGM-based coaching methodology with AI-powered insights, and expanding the clinical evidence base for the program's outcomes.

Full profile
Amgen logo

Amgen

LeaderHealthcare Tech

AI Drug Discovery

Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.

AI VisibilityBeta
Overall Score
A88
Category Rank
#3 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
87
Gemini
85

About

Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.

Full profile

AI Visibility Head-to-Head

37
Overall Score
88
#489
Category Rank
#3
81
AI Consensus
78
stable
Trend
stable
38
ChatGPT
83
40
Perplexity
87
37
Gemini
85
33
Claude
90
41
Grok
92

Key Details

Category
General
AI Drug Discovery
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Amgen
AI Drug Discovery

Integrations

Amgen is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.